Exelixis, Inc. (NASDAQ:EXEL) today announced that in the lawsuit Exelixis, Inc. (Exelixis) vs. MSN L

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that in the lawsuit

Exelixis, Inc. (EXEL) shares enjoying institutional support – up 43.5% in a year.

Allworth Financial LP bought a new position in shares of Exelixis, Inc. (NASDAQ: EXEL) in the second

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investi

NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is inves

BMO Capital analyst David Lebowitz initiates coverage on Exelixis (NASDAQ:EXEL) with a Market Per

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the

Exelixis (EXEL) Securities Investigation Notice - Levi and Korsinsky PR Newswire NEW YORK, Aug. 17,

Exelixis posted second-quarter revenue of approximately $628.7 million -- short of Wall Street conse

[url="]Schall, Brown and Schwartz[/url] LLP (“SBS”), a national shareholder rights litigation fi

LOS ANGELES--(BUSINESS WIRE)---- $EXEL--EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud

Exelixis reported an adjusted earnings beat of $0.91 per share for the second quarter. Revenue came

NEW YORK--(BUSINESS WIRE)--Exelixis (NASDAQ: EXEL) shares dropped in after-hours trading after the C

Exelixis lowered and narrowed its full-year 2026 revenue guidance, citing a slower-than-expected neu

On May 5, 2026, Exelixis management reiterated full-year 2026 financial guidance. Weeks later, the C

Arkadios Wealth Advisors bought a new position in Exelixis, Inc. (NASDAQ: EXEL) during the undefined

Amundi cut its position in Exelixis, Inc. (NASDAQ: EXEL) by 77.9% during the first quarter, accordin

Exelixis beats EPS estimates but misses on revenues; cuts 2026 outlook as a slower-than-expected NET

Truist Securities analyst Gregory Renza maintains Exelixis (NASDAQ:EXEL) with a Hold and lowers t

Stifel analyst Stephen Willey maintains Exelixis (NASDAQ:EXEL) with a Hold and raises the price t

Exelixis NASDAQ: EXEL reported second-quarter 2026 revenue of approximately $629 million, including

While the top- and bottom-line numbers for Exelixis (EXEL) give a sense of how the business performe

Exelixis, Inc. (EXEL) Q2 2026 Earnings Call Transcript

Exelixis (EXEL) came out with quarterly earnings of $0.91 per share, beating the Zacks Consensus Est

Exelixis (NASDAQ:EXEL) lowers FY2026 sales outlook from $2.525 billion-$2.625 billion to $2.500 bill

Exelixis (NASDAQ:EXEL) reported quarterly earnings of $0.91 per share which beat the analyst consens

Morgan Stanley analyst Sean Laaman maintains Exelixis (NASDAQ:EXEL) with a Equal-Weight and raise

Barclays analyst Etzer Darout maintains Exelixis (NASDAQ:EXEL) with a Equal-Weight and raises the

Wells Fargo analyst Eva Fortea Verdejo maintains Exelixis (NASDAQ:EXEL) with a Equal-Weight and r

RBC Capital analyst Leonid Timashev maintains Exelixis (NASDAQ:EXEL) with a Sector Perform and ra

Truist Securities analyst Gregory Renza maintains Exelixis (NASDAQ:EXEL) with a Hold and raises t

UBS analyst Ashwani Verma maintains Exelixis (NASDAQ:EXEL) with a Neutral and raises the price ta

HC Wainwright & Co. analyst Robert Burns reiterates Exelixis (NASDAQ:EXEL) with a Buy and mai

Wall Street analysts change outlook on top names, with downgrades and initiations. See analyst ratin

Truist Securities analyst Gregory Renza downgrades Exelixis (NASDAQ:EXEL) from Buy to Hold and ra

Citizens analyst Silvan Turkcan maintains Exelixis (NASDAQ:EXEL) with a Market Outperform and rai

Exelixis reported final STELLAR-303 data showing a survival trend for zanzalintinib combo in metasta

Exelixis, Inc. (NASDAQ:EXEL) today announced results from the final analysis of the dual primary end

STELLAR-316 is a planned phase 3 pivotal trial in patients with resected stage II/III colorectal can

Top Wall Street analysts changed their outlook on top names. See all rating changes, including upgra

HC Wainwright & Co. analyst Robert Burns maintains Exelixis (NASDAQ:EXEL) with a Buy and rais

TD Cowen analyst Yaron Werber maintains Exelixis (NASDAQ:EXEL) with a Buy and raises the price ta

Morgan Stanley analyst Sean Laaman maintains Exelixis (NASDAQ:EXEL) with a Equal-Weight and raise

Stifel analyst Stephen Willey maintains Exelixis (NASDAQ:EXEL) with a Hold and raises the price t

Wells Fargo analyst Eva Fortea Verdejo maintains Exelixis (NASDAQ:EXEL) with a Equal-Weight and r

Dr. Morrissey continued: "Our R&D organization is on track to deliver multiple milestones th

Exelixis (NASDAQ:EXEL) affirms FY2026 sales outlook from $2.525 billion-$2.625 billion to $2.525 bil

Exelixis (NASDAQ:EXEL) reported quarterly earnings of $0.87 per share which beat the analyst consens